Daniel M Kelly1, Joanne E Nettleship2, Samia Akhtar2, Vakkat Muraleedharan3, Donna J Sellers4, Jonathan C Brooke2, David S McLaren2, Kevin S Channer5, T Hugh Jones3. 1. Department of Human Metabolism, Medical School, Universiy of Sheffield, Sheffield, UK. Electronic address: daniel.kelly@sheffield.ac.uk. 2. Department of Human Metabolism, Medical School, Universiy of Sheffield, Sheffield, UK. 3. Department of Human Metabolism, Medical School, Universiy of Sheffield, Sheffield, UK; Centre for Diabetes and Endocrinology, Barnsley Hospital NHS Foundation Trust, Barnsley, UK. 4. Biomedical Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK. 5. Biomedical Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UK; Department of Cardiology, Royal Hallamshire Hospital, Sheffield, UK.
Abstract
AIMS: Non-alcoholic fatty liver disease and its precursor hepatic steatosis is common in obesity and type-2 diabetes and is associated with cardiovascular disease (CVD). Men with type-2 diabetes and/or CVD have a high prevalence of testosterone deficiency. Testosterone replacement improves key cardiovascular risk factors. The effects of testosterone on hepatic steatosis are not fully understood. MAIN METHODS: Testicular feminised (Tfm) mice, which have a non-functional androgen receptor (AR) and very low serum testosterone levels, were used to investigate testosterone effects on high-cholesterol diet-induced hepatic steatosis. KEY FINDINGS: Hepatic lipid deposition was increased in Tfm mice and orchidectomised wild-type littermates versus intact wild-type littermate controls with normal androgen physiology. Lipid deposition was reduced in Tfm mice receiving testosterone treatment compared to placebo. Oestrogen receptor blockade significantly, but only partially, reduced the beneficial effects of testosterone treatment on hepatic lipid accumulation. Expression of key regulatory enzymes of fatty acid synthesis, acetyl-CoA carboxylase alpha (ACACA) and fatty acid synthase (FASN) were elevated in placebo-treated Tfm mice versus placebo-treated littermates and Tfm mice receiving testosterone treatment. Tfm mice on normal diet had increased lipid accumulation compared to littermates but significantly less than cholesterol-fed Tfm mice and demonstrated increased gene expression of hormone sensitive lipase, stearyl-CoA desaturase-1 and peroxisome proliferator-activated receptor-gamma but FASN and ACACA were not altered. SIGNIFICANCE: An action of testosterone on hepatic lipid deposition which is independent of the classic AR is implicated. Testosterone may act in part via an effect on the key regulatory lipogenic enzymes to protect against hepatic steatosis.
AIMS: Non-alcoholic fatty liver disease and its precursor hepatic steatosis is common in obesity and type-2 diabetes and is associated with cardiovascular disease (CVD). Men with type-2 diabetes and/or CVD have a high prevalence of testosterone deficiency. Testosterone replacement improves key cardiovascular risk factors. The effects of testosterone on hepatic steatosis are not fully understood. MAIN METHODS: Testicular feminised (Tfm) mice, which have a non-functional androgen receptor (AR) and very low serum testosterone levels, were used to investigate testosterone effects on high-cholesterol diet-induced hepatic steatosis. KEY FINDINGS: Hepatic lipid deposition was increased in Tfm mice and orchidectomised wild-type littermates versus intact wild-type littermate controls with normal androgen physiology. Lipid deposition was reduced in Tfm mice receiving testosterone treatment compared to placebo. Oestrogen receptor blockade significantly, but only partially, reduced the beneficial effects of testosterone treatment on hepatic lipid accumulation. Expression of key regulatory enzymes of fatty acid synthesis, acetyl-CoA carboxylase alpha (ACACA) and fatty acid synthase (FASN) were elevated in placebo-treated Tfm mice versus placebo-treated littermates and Tfm mice receiving testosterone treatment. Tfm mice on normal diet had increased lipid accumulation compared to littermates but significantly less than cholesterol-fed Tfm mice and demonstrated increased gene expression of hormone sensitive lipase, stearyl-CoA desaturase-1 and peroxisome proliferator-activated receptor-gamma but FASN and ACACA were not altered. SIGNIFICANCE: An action of testosterone on hepatic lipid deposition which is independent of the classic AR is implicated. Testosterone may act in part via an effect on the key regulatory lipogenic enzymes to protect against hepatic steatosis.
Authors: Frode Norheim; Simon T Hui; Emre Kulahcioglu; Margarete Mehrabian; Rita M Cantor; Calvin Pan; Brian W Parks; Aldons J Lusis Journal: J Lipid Res Date: 2016-11-03 Impact factor: 5.922
Authors: Yue Jia; Jennifer K Yee; Christina Wang; Liana Nikolaenko; Maruja Diaz-Arjonilla; Joshua N Cohen; Samuel W French; Peter Y Liu; YanHe Lue; Wai-Nang P Lee; Ronald S Swerdloff Journal: Am J Physiol Endocrinol Metab Date: 2017-09-19 Impact factor: 4.310
Authors: Monika Sarkar; Melissa Wellons; Marcelle I Cedars; Lisa VanWagner; Erica P Gunderson; Veeral Ajmera; Laura Torchen; David Siscovick; J Jeffrey Carr; James G Terry; Mary Rinella; Cora E Lewis; Norah Terrault Journal: Am J Gastroenterol Date: 2017-03-14 Impact factor: 10.864
Authors: Maryam Nasiri; Nikolaos Nikolaou; Silvia Parajes; Nils P Krone; George Valsamakis; George Mastorakos; Beverly Hughes; Angela Taylor; Iwona J Bujalska; Laura L Gathercole; Jeremy W Tomlinson Journal: Endocrinology Date: 2015-05-14 Impact factor: 4.736